Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: Imbalance of prefrontal serotonergic and dopaminergic functions

Neuropsychopharmacology

Volumn 23, Issue 4, 2000, Pages 375-387

  Noda, Yukihiro ^a   Kamei, Hiroyuki ^a   Mamiya, Takayoshi ^a   Furukawa, Hiroshi ^b   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

Dopamine; Immobility; Negative symptom; Phencyclidine; Prefrontal cortex; Serotonin

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5,7 DIHYDROXYTRYPTAMINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; LEVOMEPROMAZINE; METHYLPHENIDATE; OLANZAPINE; PHENCYCLIDINE; PIMOZIDE; RISPERIDONE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NEGATIVE SYNDROME; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SEROTONIN METABOLISM; SEROTONINERGIC SYSTEM;

ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE; HALLUCINOGENS; IMMOBILIZATION; MALE; MICE; MOTOR ACTIVITY; PHENCYCLIDINE; PREFRONTAL CORTEX; SCHIZOPHRENIA; SEROTONIN; STRESS;

EID: 0033828218     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00138-X     Document Type: Article

References (55)

1. Angrist B., Rotrosen J., Gershon S. Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacology. 72:1980;17-19.
2. Barnes T.R.E., Curson D.A., Liddle P.F., Patel M. The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry. 154:1989;486-491.
3. Beskow J., Gottfries C.G., Roos B.E., Winblad B. Determination of monoamine and monoamine metabolites in the human brain. Post mortem studies in a group of suicides and a control group Acta Psychiat Scand. 53:1976;7-20.
4. Bleich A., Brown S.L., Kahn R., Van Praag H.M. The role of serotonin in schizophrenia. Schizophr Bull. 14:1988;297-315.
5. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1988;379-382.
6. Castelao F., Ferreira L., Gelders Y.G., Heilen S.L.E. The efficacy of the D2 and 5-HT-2 antagonist risperidone (R 64766) in the treatment of chronic psychosis. An open dose-finding study Schizophrenia Res. 2:1989;411-415.
7. Castellani S., Adams P.M. Acute and chronic phencyclidine effects on locomotor activity, stereotypy and ataxia in rats. Eur J Pharmacol. 73:1981;143-154.
8. Chiodo L.A., Bannon M.J., Grace A.A., Roth R.H. Evidence for the absence on impulse regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons. Neuroscience. 12:1984;1-16.
9. Cochran E., Robins E., Grote S. Regional serotonin levels in brain. A comparison of depressive suicides and alcoholic suicides with controls Bio Psychiatry. 11:1976;283-294.
10. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex. Interactions of central dopamine systems and the pathogenesis of schizophrenia J Neural Transm. 36:1992;61-89.
11. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521:1990;311-315.
12. Elizur A., Davidson S. The evaluation of the anti-autistic activity of sulpiride. Cur Ther Res. 18:1975;578-584.
13. Fuller R.W., Snoddy H.D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol. 77:1992;87-93.
14. Galloway M.P., Wolf M.E., Roth R.H. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors. Studies in vivo J Pharmacol Exp Ther. 236:1986;689-698.
15. Gelenberg A.J., Doller J.C. Clozapine versus chlorpromazine for the treatment of schizophrenia. Preliminary results from a double-blind study J Clin Psychiatry. 40:1979;238-240.
16. Goldman-Rakic P.S. Prefrontal cortical dysfunction in schizophrenia. The relevance of working memory Carroll B.J., Barrett J.E. Psychopathology and the Brain. 1991;1-23 Raven Press, New York.
17. Haase H.J., Floru L., Ulrich F. Clinical-neuroleptic investigation of N-[(l-ethyl-pyrrolidine-2-yl)-methyl]-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutely ill schizophrenics. Int Pharmacopsychiatry. 9:1974;77-94.
18. Haroutunian V., Knott P., Davis K.L. Effects of mesocortical dopamine lesions upon subcortical dopaminergic function. Psychopharmacol Bull. 24:1988;341-344.
19. Hiramatsu M., Cho A.K., Nabeshima T. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol. 166:1989;359-366.
20. Ital T., Keskiner A., Kiremitci N., Holden J.M.C. Effect of phencyclidine in chronic schizophrenics. Can Psychiatric Assoc J. 12:1967;209-212.
21. Janssen P.A.J., Niemegeers C.J.E., Awouters F., Schellekens K.H.L., Megens A.A.H.P., Meert T.F. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 244:1988;685-693.
22. Javitt D.C., Zukin S.R. The role of excitatory amino acids in neuropsychiatric illness. J Neuropsychiatry Clin Neurosci. 2:1990;44-52.
23. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
24. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Linde J.-P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
25. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine. From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology. 20:1999;201-225.
26. Jentsch J.D., Tran A., Le D., Youngren K.D., Phil M., Roth R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99.
27. 3H-TCP binding to rat cortical membranes. Effects of divalent cations and glycine Domino E.F., Kamenka J.M. Proceedings of the Second U.S.-French Sponsored International Seminar. Sigma and Phencyclidine-like Compounds as Molecular Probes in Biology:1987;259-268 Ann Arbor MI, New York.
28. Kahn R.S., Davis K.L. New developments in dopamine and schizophrenia. Bloom F.E., Kupfer D.J. Psychopharmacology. The Fourth Generation of Progress:1995;1193-1204 Raven Press, New York.
29. Kapur S., Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 153:1996;466-476.
30. Knable M.B., Weinberger D.R. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacology. 11:1997;123-131.
31. Kolachana B.S., Saunders R.C., Weinberger D.R. Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus. An in vivo neurochemical assessment in the rhesus monkeys Neuroscience. 69:1995;859-868.
32. Leccese A.P., Lyness W.H. Lesions of the dopamine neurons in the median prefrontal cortex. Effects on self-administration of amphetamine and dopamine synthesis in the brain of the rat Neuropharmacology. 26:1987;1303-1308.
33. Lieberman J.A., Kane J.M., Johns C.A. Clozapine. Guidelines for clinical management J Clin Psychiatry. 50:1989;329-338.
34. Löscher W., Annies R., Honack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett. 128:1991;191-194.
35. Luby E.D., Cohen B.D., Rosenbaum G., Gottlieb J.S., Kelley R. Study of a new schizophrenomimetic drug Sernyl. Arch Neurol Psychiatry. 81:1959;363-366.
36. Maddox V.H., Godefroi E.F., Parcell R.F. The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem. 8:1965;230.
37. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine. The dopamine-serotonin hypothesis of schizophrenia Psychopharmacology. 99:1989;S18-S27.
38. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21(2 Suppl):1999;106S-115S.
39. Nabeshima T., Fukaya H., Ymamaguchi K., Ishikawa K., Furukawa H., Kameyama T. Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur J Pharmacol. 135:1987;23-33.
40. Noda Y., Yamada K., Furukawa H., Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine. A new model of schizophrenia Br J Pharmacol. 116:1995;2531-2537.
41. Noda Y., Mamiya T., Furukawa H., Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol. 324:1997;135-140.
42. Noda Y., Miyamato Y., Mamiya T., Kamei H., Furukawa H., Nabeshima T. Involvement of dopaminergic system in phencyclidine-induced place preference in mice pretreated with phencyclidine repeatedly. J Pharmacol Exp Ther. 286:1998;44-51.
43. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats. A new model sensitive to antidepressant treatments Eur J Pharmacol. 47:1978;379-391.
44. Porsolt R.D., Bertin A., Jalfre M. Behavioural despair in mice. A primary screening test for antidepressants Arch Int Pharmacodym. 229:1977;327-336. a.
45. Porsolt R.D., Lepichon M., Jalfre M. Depression. A new animal model sensitive to antidepressant treatments Nature. 266:1977;730-732. b.
46. Pycock C.J., Kerwin R.W., Carter C.J. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 286:1980;74-76.
47. Rosin D.L., Clark W.A., Goldstein M., Roth R.H., Doutch A.Y. Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in mesolimbic and nigrostriatal dopamine systems. Neuroscience. 48:1992;831-839.
48. Sams-Dodd F. Phencyclidine-induced stereotyped behavior and social isolation in rats. A possible animal model of schizophrenia Behav Pharmacol. 7:1996;3-23.
49. Schlemmer R.F., Davis J.M. A comparison of three psychotomimetic-induced models of psychosis in nonhuman primate social colonies. Prog Clin Biol Res. 131:1983;33-78.
50. Steinpreis R.E. The behavioral and neurochemical effects of phencyclidine in humans and animals. Some implications for modeling psychosis Behav Brain Res. 74:1996;45-55.
51. Thierry A.M., Blanc G., Sobel A., Stinus L., Glowinski J. Dopaminergic terminals in the rat cortex. Science. 182:1973;499-501.
52. Tollefson G.D., Sanger T.M. Negative symptoms. A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine Am J Psychiatry. 154:1997;466-474.
53. van Praag H.M. Indoleamines in depression. Usdin E., Hamburg D.A., Barchas J.D. Neuroregulators and Psychiatric Disorders. 1977;163-176 Oxford Univ Press, New York.
54. Williams S.M., Goldman-Rakic P.S. Characterization of the dopaminergic innervation of the primate frontal cortex using a dopamine-specific antibody. Cerebral Cortex. 3:1993;199-222.
55. Wilmot C.A., Szczepanik A.M. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res. 487:1989;288-298.